Bio-protocol

bio-protocol.org

Bio-protocol (ISSN: 2331-8325) is an e-journal created in 2011 by a group of Stanford researchers. Our mission is to make life science research more efficient and reproducible by curating high quality, open-access, life science protocols. We differ from other journals and online protocol depositories in a number of ways. We are free to publish with and we are free to use. Our protocols are of the highest quality because publication is by invitation only, and all of our articles undergo extensive peer review to ensure reproducibility.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

INSEMPRA ANNOUNCES STRATEGIC INVESTMENT IN SOLENA MATERIALS

Insempra, | July 26, 2022

news image

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating ...

Read More

Medical

AGILENT ANNOUNCES COLLABORATION WITH APC ON REAL-TIME PROCESS MONITORING

Agilent Technologies | May 31, 2022

news image

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which a...

Read More

Cell and Gene Therapy

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

news image

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More

MedTech

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

news image

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More
news image

MedTech

INSEMPRA ANNOUNCES STRATEGIC INVESTMENT IN SOLENA MATERIALS

Insempra, | July 26, 2022

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating ...

Read More
news image

Medical

AGILENT ANNOUNCES COLLABORATION WITH APC ON REAL-TIME PROCESS MONITORING

Agilent Technologies | May 31, 2022

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which a...

Read More
news image

Cell and Gene Therapy

EVONETIX DEMONSTRATES NOVEL ENZYMATIC DNA SYNTHESIS METHOD

EVONETIX LTD | March 02, 2022

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabli...

Read More
news image

MedTech

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us